Pharmacokinetics of Intravitreal Bevacizumab (Avastin)

Ophthalmology

Volumn 114, Issue 5, 2007, Pages 855-859

  Bakri, Sophie J ^a   Snyder, Melissa R ^a   Reid, Joel M ^a   Pulido, Jose S ^a   Singh, Ravinder J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; ENUCLEATION; EYE; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SERUM; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; AQUEOUS HUMOR; HALF-LIFE; MALE; RABBITS; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 34247400587     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2007.01.017     Document Type: Article

References (20)

1. Rosenfeld P.J., Moshfeghi A.A., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36 (2005) 331-335
2. Rich R.M., Rosenfeld P.J., Puliafito C.A., et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26 (2006) 495-511
3. Spaide R.F., Laud K., Fine H.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (2006) 383-390
4. Rosenfeld P.J., Fung A.E., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36 (2005) 336-339
5. Iturralde D., Spaide R.F., Meyerle C.B., et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26 (2006) 279-284
6. Spaide R.F., and Fisher Y.L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26 (2006) 275-278
7. Avery R.L. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26 (2006) 352-354
8. Bakri S.J., Donaldson M.J., and Link T.P. Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. [letter]. Eye 20 (2006) 1474-1475
9. Bakri S.J., Cameron J.D., McCannel C.A., et al. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 142 (2006) 162-164
10. Manzano R.P., Peyman G.A., Khan P., and Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26 (2006) 257-261
11. Maturi R.K., Bleau L.A., and Wilson D.L. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 26 (2006) 270-274
12. Luthra S., Narayanan R., Marques L.E., et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 26 (2006) 512-518
13. Bakri S.J., Snyder M.R., Pulido J.S., et al. Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 26 (2006) 519-522
14. Malhotra B.K., Brundage R.C., Lemaire M., and Sawchuk R.J. Modeling the route of administration-based enhancement in the brain delivery of EAB 515, studied by microdialysis. J Drug Target 4 (1997) 277-288
15. D'Argenio D.Z., and Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9 (1979) 115-134
16. Iyer M.N., He F., Wensel T.G., et al. Clearance of intravitreal moxifloxacin. Invest Ophthalmol Vis Sci 47 (2006) 317-319
17. Fauser S., Kalbacher H., Alteheld N., et al. Pharmacokinetics and safety of intravitreally delivered etanercept. Graefes Arch Clin Exp Ophthalmol 242 (2004) 582-586
18. Scholes G.N., O'Brien W.J., Abrams G.W., and Kubicek M.F. Clearance of triamcinolone from vitreous. Arch Ophthalmol 103 (1985) 1567-1569
19. Gaudreault J., Fei D., Rusit J., et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46 (2005) 726-733
20. Avery R.L., Pearlman J., Pieramici D.J., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113 (2006) 1695-1705